Esophagus, Stomach & Upper GI · Article 114

How Should Gastric Neuroendocrine Tumors Be Classified and Managed?

Gastric neuroendocrine tumors requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

Gastric neuroendocrine tumors clinical reference — Related free clinical resource: Endoscopy and Diagnostic Imaging.

Gastric neuroendocrine tumors: practical clinical approach

This page focuses on Gastric neuroendocrine tumors with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for Gastric neuroendocrine tumors

Clinical takeaway: For Gastric neuroendocrine tumors, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: Gastric neuroendocrine tumors (gNETs) should first be placed into their biologic context. Type 1 tumors arise in autoimmune atrophic gastritis with hypergastrinemia and are usually multiple, small and indolent. Type 2 tumors are associated with gastrinoma/MEN1 and are also gastrin-driven. Sporadic type 3 tumors are not driven by hypergastrinemia and have substantially greater metastatic potential. Management therefore depends on type, size, grade, depth and metastatic risk rather than the label ‘gastric NET’ alone.

Type 1: the common indolent pattern

Type 1 gNETs occur in autoimmune gastritis. Endoscopy often reveals multiple small nodules in the body/fundus. Gastrin is elevated because of achlorhydria. Small lesions are usually removed endoscopically and followed because new lesions can recur.

Type 2: think gastrinoma and MEN1

Type 2 gNETs are associated with gastrinoma, often in MEN1. Gastrin is elevated but gastric acid secretion is increased rather than absent. The clinical task includes locating and managing the gastrinoma in addition to treating gastric lesions.

Type 3: treat as a higher-risk neoplasm

Sporadic type 3 tumors occur without the classic hypergastrinemic background. They are more often solitary and larger, with greater risk of invasion and metastasis. Cross-sectional imaging, EUS and oncologic/surgical staging are more important.

Grade and depth still matter

Pathology should report differentiation, grade and Ki-67 proliferative index. EUS is useful for larger lesions or when depth of invasion is uncertain. Treatment ranges from simple endoscopic removal to advanced endoscopic resection, surgery and systemic therapy.

Practical clinical algorithm

Confirm neuroendocrine histology and obtain grade/Ki-67.
Measure gastrin in the appropriate clinical context and assess background gastric mucosa.
Classify as type 1, type 2 or sporadic/type 3.
For type 1 disease, remove appropriate small lesions and survey for recurrence.
For suspected type 2 disease, evaluate for gastrinoma/MEN1.
For type 3, larger, higher-grade or invasive lesions, stage with EUS/imaging and involve oncology/surgery.

Common mistakes to avoid

Managing all gastric NETs as equivalent.
Measuring gastrin without considering PPI therapy and achlorhydria.
Ignoring the background gastric biopsies.
Understaging a solitary larger type 3 lesion.
Failing to provide surveillance for recurrent type 1 disease.

Trainee takeaway

The most important first step is biologic classification. Type 1 and type 3 gastric NETs may look similar endoscopically but behave very differently.

Frequently asked questions

Are all type 1 gastric NETs resected?

Small lesions are commonly removed endoscopically, but management can be individualized according to number, size and recurrence burden.

Why is gastrin high in type 1 and type 2 disease?

Type 1 reflects achlorhydria from autoimmune gastritis; type 2 reflects autonomous gastrin secretion from a gastrinoma.

When is EUS useful?

For larger lesions, uncertain depth, suspected muscularis involvement or higher-risk disease.

References

1. Thomson ABR. Endoscopy and Diagnostic Imaging. Part I. CAPstone Academic Publishers; 2012.

2. Thomson ABR. Images in Gastroenterology and Hepatology. Part 1. CAPstone Academic Publishers; 2021.

3. Panzuto F, Ramage J, Pritchard DM, et al. ENETS 2023 guidance paper for gastroduodenal neuroendocrine tumours G1-G3. J Neuroendocrinol. 2023;35:e13306.

4. Shah SC, Piazuelo MB, Kuipers EJ, Li D. AGA Clinical Practice Update on Atrophic Gastritis. Gastroenterology. 2021;161:1325-1332.e7.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions